Comparing Pediatrix Medical Group and Amarantus Bioscience Stocks

Investors are evaluating the comparative strengths of two medical companies: Pediatrix Medical Group (NYSE:MD) and Amarantus Bioscience (OTCMKTS:AMBS). The analysis focuses on profitability, analyst recommendations, dividends, institutional ownership, earnings, risk, and valuation to determine which stock might offer better investment potential.

Volatility and Risk Assessment

The risk profiles of these companies differ significantly. Pediatrix Medical Group has a beta of 0.73, indicating that its share price is 27% less volatile than the broader S&P 500 index. In contrast, Amarantus Bioscience has a beta of 1.59, making its stock 59% more volatile than the S&P 500. This suggests that while Pediatrix may offer more stability, Amarantus could present higher risk and reward potential for investors.

Ownership and Analyst Insights

Institutional investors hold a substantial 97.7% of Pediatrix Medical Group‘s shares, reflecting strong confidence from large financial entities in its long-term performance. In comparison, only 0.9% of Pediatrix’s shares are owned by company insiders. For Amarantus Bioscience, insider ownership stands at 10.3%, indicating a lower level of institutional support.

Analyst recommendations provide further context. Current ratings from MarketBeat indicate a more favorable outlook for Pediatrix compared to Amarantus, with several analysts endorsing Pediatrix as a stronger investment.

Earnings and Profitability Comparison

When examining the financial metrics, Pediatrix Medical Group demonstrates a stronger overall performance. It consistently outperforms Amarantus Bioscience in eight out of eleven evaluated factors, including net margins, return on equity, and return on assets. Notably, while Amarantus has lower revenue, it reports higher earnings per share, showcasing a different approach to profitability.

Pediatrix specializes in providing comprehensive medical services, including neonatal and pediatric care, alongside maternal-fetal services. Established in 1979 and based in Sunrise, Florida, the company has a long history of operational success. Its recent name change from MEDNAX, Inc. to Pediatrix Medical Group in July 2022 reflects a strategic rebranding to focus on its core services.

Conversely, Amarantus Bioscience Holdings, Inc., founded in 2008 and headquartered in New York City, emphasizes the development of innovative diagnostic and therapeutic solutions in neurology and regenerative medicine. Its product pipeline includes a blood test for Alzheimer’s disease and a drug for Parkinson’s disease-related symptoms.

In conclusion, while Pediatrix Medical Group displays stronger metrics and institutional backing, Amarantus Bioscience offers unique opportunities within niche medical markets. Investors should consider their risk tolerance and investment goals when comparing these two companies.